FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:301-304 January 20, 2005 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Liu, B. A. Related Article Related Article by Ray, W. A. PubMed Citation

To the Editor: Ray and colleagues (Sept. 9 issue)¹ seem to have overlooked several important issues when describing the association of erythromycin with the risk of sudden death from cardiac causes. First, was there a higher risk associated with any specific erythromycin preparations? The most recent edition of The Use of Antibiotics, edited by Kucers et al., lists six available erythromycin preparations (base, stearate, estolate, ethylsuccinate, ascitrate, and parenteral erythromycin).² Can the authors differentiate the risks associated with these preparations?

Second, the authors mention clarithromycin as "a strong CYP3A inhibitor," yet they consider this antibiotic separately and do not offer . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.